Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fumaria officinalis L., commonly known as fumitory, is a plant traditionally valued in European and Asian herbal medicine. Its phytochemical composition is rich in isoquinoline alkaloids, such as protopine and stylopine, and various phenolic compounds including caffeoylmalic acid, quercetin dihexoside, rutin, and methylquercetin dihexoside. Scientific investigations highlight its potential for anti-inflammatory, hepatoprotective, and antioxidant activities. Specific compounds like stylopine have been identified as potential cyclooxygenase-2 (COX-2) inhibitors. The plant extract also demonstrates cytotoxic effects against leukemia and multiple myeloma cell lines and promotes diabetic wound healing by upregulating genes for vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF-β), and fibroblast growth factor 2 (b-FGF). Formulations incorporating Fumaria officinalis extracts, such as nano-liposomal carriers and chitosan nanoparticles, are being explored for dermal applications and wound dressings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fumaria officinalis.